Eli Lilly & Co. has filed a patent infringement suit against Watson Pharmaceuticals Inc. over the rival drugmaker’s plans to market a generic version of postmenopausal osteoporosis treatment Evista®. The complaint argues that Watson’s abbreviated new drug application to market generic Evista® will lead to direct infringement of three patents. Lilly has previously sued several generic makers and successfully blocked Teva from launching generic Evista®. Lilly is represented in this matter by Finnegan.
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
April 11, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.